173336-02-2

Upstream product

• 145589-03-3 (R)-4-benzyl-3-(3-methylbutyryl)oxazolidin-2-one 
• 198641-43-9 3-acetoxy-4-tert-butyl-benzyl bromide 
• 88-60-8 2-tert-Butyl-5-methylphenol 
• 198641-42-8 acetic acid-(2-tert-butyl-5-methyl-phenyl ester) 
• 198641-45-1 3-[2(R)-isopropyl-3-(3-acetoxy-4-tert-butyl-phenyl)-propanoyl]-4(R)-benzyl-oxazolidin-2-one 
• 7664-93-9 sulfuric acid 
• 7732-18-5 water 
• 100-53-8 phenylmethanethiol 

Downstream Products

• 198641-73-5 N-tert-butoxycarbonyl-2-methylene-4(S)-hydroxy-5(S)-amino-7(S)-isopropyl-8-(3-benzyloxy-4-tert-butyl-phenyl)-octanoic acid (N-butyl) amide 
• 198641-75-7 {(1S,2S)-1-[(S)-2-(3-Allyloxy-4-tert-butyl-benzyl)-3-methyl-butyl]-4-butylcarbamoyl-2-hydroxy-pentyl}-carbamic acid tert-butyl ester 
• 198641-71-3 (2S,4S)-4-(3-Benzyloxy-4-tert-butyl-benzyl)-2-tert-butoxycarbonylamino-5-methyl-hexanoic acid methyl ester 
• 198641-74-6 {(1S,2S)-4-Butylcarbamoyl-1-[(S)-2-(4-tert-butyl-3-hydroxy-benzyl)-3-methyl-butyl]-2-hydroxy-pentyl}-carbamic acid tert-butyl ester 
• 198641-72-4 [(1S,3S)-3-(3-Benzyloxy-4-tert-butyl-benzyl)-1-formyl-4-methyl-pentyl]-carbamic acid tert-butyl ester 
• 198641-68-8 2-Benzyloxy-4-((R)-2-bromomethyl-3-methyl-butyl)-1-tert-butyl-benzene 
• 173336-01-1 2(R)-isopropyl-3-(3-benxyloxy-4-tert-butyl-phenyl)-propanol 

Relevant academic research and scientific papers

METHODS OF TREATING ALZHEIMER'S DISEASE USING ARYL ALKANOIC ACID AMIDES

Disclosed are methods for treating Alzheimer’s disease, and other diseases, and/or inhibiting beta-secretase enzyme, and/or inhibiting deposition of A beta peptide in a mammal, by use of compounds of formula 1 (1) wherein the variables R1-R8 and X are defined herein.

Design and synthesis of novel 2,7-dialkyl substituted 5(S)-amino-4(S)-hydroxy-8-phenyl-octanecarboxamides as in vitro potent peptidomimetic inhibitors of human renin

Novel low-molecular weight transition-state peptidomimetic renin inhibitors characterized by an all-carbon 8-phenyl substituted octanecarboxamide skeleton have been discovered based on a topographical design approach. The in vitro most potent inhibitors 21, 25 and 26 incorporating a strong H-bond acceptor group linked to the benzyl spacer of the (P3-P1)-unit had IC50s in the low nanomolar range against human renin.